Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals is attractive fundamentally because its high-margin royalty aggregation model produces recurring cash flows from a diversified base of 15 major commercial-stage royalty streams and 200+ additional programs, while Captisol and milestone income add further optionality. Q3/26 revenue of $78.7MM and adj. core EPS of $2.67 both beat estimates, and management raised 2026 EPS guidance to $9.50–$9.75/share as royalty strength from Filspari, Ohtuvayre, and newly acquired XOMA assets accelerated. The balance sheet, with $447.4MM in cash and roughly $750MM of deployable capital, supports accretive acquisitions and pipeline upside, while upcoming catalysts such as Qtorin rapamycin’s PDUFA on Feb. 28, 2027 and up to 7 pivotal readouts through 2027 could sustain growth.

Ligand Pharmaceuticals is viewed negatively because its valuation depends heavily on royalty streams and Captisol revenues that could weaken if commercial products face competition, sales slow, or manufacturing and IP issues arise. The downside scenario assumes no terminal value after 10-years, which implies that newly commercialized products and pipeline drugs could perform well below expectations or that a value-destructive deal could erode long-term cash flows. Additional pressure comes from clinical trial setbacks, approval and reimbursement risk, acquisition integration risk, financing uncertainty, and potential tax liabilities tied to the prior distribution/merger under 368(a).